High-intensity Interval Training in Patients With Spinal Muscular Atrophy

Status Recruiting

Clinical Trial Summary

Patients with spinal muscular atrophy who are wheelchair users often experience lower back - and gluteal pain, reduced sleep quality, constipation and reduced quality of life - symptoms that regular exercise could potentially alleviate. However, only very little research has been done on exercise for patients who are wheelchair users. The aim of this study is to explore the impact of cycle exercise on patients with spinal muscular atrophy.

Clinical Trial Description

Spinal muscular atrophy (SMA) is a neuromuscular disease affecting the motor neurons of the spinal cord that innervate the skeletal muscles, leading to progressive muscle atrophy and weakness. Consequently, many patients end up having to use a wheelchair from an early age. Besides the impaired motor function, patients with SMA can also experience a variety of symptoms associated with their disease, a sedentary lifestyle and physical inactivity such as lower back and leg pain, obstipation, reduced sleep quality and impacted quality of life. Training can help alleviate these symptoms in patients with neuromuscular diseases. However, there isn´t any validated way for patients with SMA to train as of today. Research has shown that high-intensity interval training (HIIT) has been well tolerated among patients with SBMA, a disease resembling SMA with patients tolerating this form for training well. The aim of this study is to investigate:(1) if HIIT could be exercise modality in SMA patients (2) and to see what positive effects exercise has for their impaired motor function and related challenges. The investigators will test the participants at baseline, which will be followed by a 8-week control period. After the control period the participants will be tested again before the intervention period. During the intervention period the participants will have to train 5 times a week for 10 minutes. After the intervention period, there will be a final test day, where the final results will be compared with those from the baseline. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06368076
Study type	Interventional
Source	Rigshospitalet, Denmark
Contact	Sophia Frølich, stud.med
Phone	+ 45 3545 3561
Email	sophia.vera.froelich.01@regionh.dk
Status	Recruiting
Phase	N/A
Start date	January 9, 2024
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04851873` - Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)	Phase 3
Completed	`NCT03223051` - Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy	N/A
Completed	`NCT04335942` - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor	N/A
Recruiting	`NCT05794139` - Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy	Phase 2
Completed	`NCT02003937` - Aerobic Training in Patients With Spinal Muscular Atrophy Type III	N/A
Not yet recruiting	`NCT00961103` - Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)	N/A
Completed	`NCT00227266` - Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Phase 2
Completed	`NCT00374075` - Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy	Phase 1
Enrolling by invitation	`NCT05539456` - Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
Recruiting	`NCT05779956` - Personalized Medicine for SMA: a Translational Project
Recruiting	`NCT03217578` - Neonatal Spinal Muscular Atrophy (SMA) Screening
Recruiting	`NCT03300869` - Natural History of Types 2 and 3 SMA in Taiwan
Completed	`NCT01703988` - An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy	Phase 1/Phase 2
Withdrawn	`NCT02235090` - Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting	N/A
Completed	`NCT02123186` - Newborn Screening for Spinal Muscular Atrophy	N/A
Completed	`NCT00756821` - A Pilot Study of Biomarkers for Spinal Muscular Atrophy	N/A
Completed	`NCT00004771` - Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease	Phase 2
Recruiting	`NCT05366465` - Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
Recruiting	`NCT06310421` - Spinal Muscular Atrophy Neonatal Screening Program
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.